Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
58.50
-2.45 (-4.02%)
Sep 10, 2026, 11:57 AM HKT

HKG:2315 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
366.3173.233.54-382.95-601.95-545.58
Depreciation & Amortization
129.21132.65135.24179.3174.1128.1
Other Amortization
27.8127.8133.933.15--
Loss (Gain) From Sale of Assets
-1-10-1.830.08-0.39
Asset Writedown & Restructuring Costs
0.220.22-0.01---
Loss (Gain) From Sale of Investments
20.120.130.11-0.15-44.7-2.13
Loss (Gain) on Equity Investments
---10.0314.770.4
Stock-Based Compensation
35.2435.2422.6430.9815.3127.75
Provision & Write-off of Bad Debts
11.5111.519.454.281.423.12
Other Operating Activities
-108.3223.2183.5589.842.0433.13
Change in Accounts Receivable
-59.69-59.69-103.69-39.02-4.59-35.86
Change in Inventory
-15.6-15.6-17.193.79-6.4-29.96
Change in Accounts Payable
25.7425.74-14.6511.947.3519.04
Change in Unearned Revenue
---9.98-8.0716.75
Change in Income Taxes
-----0.8-
Change in Other Net Operating Assets
-3.08-3.081.174.168.1719.86
Operating Cash Flow
428.38370.25211.25-76.65-303.27-365.78
Operating Cash Flow Growth
11.25%75.27%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-276.74-87.82-37.13-126.62-240.27-198.67
Sale of Property, Plant & Equipment
2.220.291.1126.341.644.76
Divestitures
-----6.86-
Investment in Securities
-325.6-98.12-101.09-91.76109.78
Other Investing Activities
0.790.79----
Investing Cash Flow
-599.33-184.86-137.12-100.28-153.74-84.13

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-248.27235.67319.91209.6-
Short-Term Debt Repaid
---2---
Long-Term Debt Repaid
--386.76-303.81-172.98-68.77-57.13
Lease Payments
-40-41.18-36.16-22.16-21.57-14.98
Total Debt Repaid
-535.27-386.76-305.81-172.98-68.77-57.13
Net Debt Issued (Repaid)
-253.33-138.49-70.15146.93140.83-57.13
Issuance of Common Stock
1,1691,169--521.06311.04
Repurchase of Common Stock
-9.21-18.07-9.51-8.2-18.99-
Common Dividends Paid
-15.05-15.05-15.19---
Other Financing Activities
-346.45-17.322.82-176.55-55.69-34.47
Financing Cash Flow
544.75979.86-92.03-37.82587.2219.44

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-5.342.842.753.4714.24-0.38
Net Cash Flow
368.461,168-15.15-211.28144.44-230.85

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
151.64282.43174.12-203.26-543.54-564.45
Free Cash Flow Growth
-55.22%62.21%----
Free Cash Flow Margin
8.92%20.48%17.76%-28.35%-101.81%-159.20%
Free Cash Flow Per Share
0.360.700.41-0.51-1.43-1.56
Levered Free Cash Flow
31.99434.9-0.26-231.5-423.55-397.16
Unlevered Free Cash Flow
76.42479.2857.04-169.1-388.46-372.52
Free Cash Flow After Leases
111.64241.25137.96-225.42-565.11-579.42

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1.72--24.08177.66
Cash Income Tax Paid
51.849.0734.050.64--
Change in Working Capital
-52.68-52.68-137.22-9.2495.65-10.18